ArticleCureus2025
Unique Gender-Related Characteristics and Differences of Chronic Myeloid Leukemia Patients in Azerbaijan: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to evaluate gender-related demographic, clinical, and molecular differences, and imatinib response in patients with chronic myeloid leukemia (CML) in Azerbaijan.
settingThe study was carried out at National Hematology and Blood Transfusion Center, Baku, Azerbaijan. PERIOD: This is a retrospective data analysis carried out from January 2008 to December 2023.
methodsA total of 763 patients with Ph+ CML were included. Case records were reviewed for demographic data, disease phase, risk group, clinical manifestation, molecular characteristics, and response to imatinib. Genetic mutations were analyzed in 163 patients.
resultsA total of 763 CML patients were analyzed, with a female predominance (54%) observed, an atypical trend compared to global data. Female patients had significantly smaller spleen sizes, lower hemoglobin, and higher platelet counts than male patients. Imatinib response was better in female patients (55.2%) compared to male patients (44.8%) (p = 0.03). ABL kinase domain mutations were significantly more frequent in male patients (21.3%) than in female patients (six percent) (p = 0.004), with T315I mutation also higher in male patients (p = 0.036). Survival analysis showed significantly better overall survival in female patients (p = 0.038), although subgroup differences by risk category were not statistically significant.
conclusionThis study highlights significant gender-related differences in CML patients in Azerbaijan, including a unique female predominance, better treatment response, and superior survival outcomes in women. These findings underscore the need to consider gender as a relevant factor in CML prognosis, treatment planning, and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.